Literature DB >> 15381514

Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk.

Kay-Tee Khaw1, Nicholas Wareham, Sheila Bingham, Robert Luben, Ailsa Welch, Nicholas Day.   

Abstract

BACKGROUND: Increasing evidence suggests a continuous relationship between blood glucose concentrations and cardiovascular risk, even below diagnostic threshold levels for diabetes.
OBJECTIVE: To examine the relationship between hemoglobin A1c, cardiovascular disease, and total mortality.
DESIGN: Prospective population study.
SETTING: Norfolk, United Kingdom. PARTICIPANTS: 4662 men and 5570 women who were 45 to 79 years of age and were residents of Norfolk. MEASUREMENTS: Hemoglobin A1c and cardiovascular disease risk factors were assessed from 1995 to 1997, and cardiovascular disease events and mortality were assessed during the follow-up period to 2003.
RESULTS: In men and women, the relationship between hemoglobin A1c and cardiovascular disease (806 events) and between hemoglobin A1c and all-cause mortality (521 deaths) was continuous and significant throughout the whole distribution. The relationship was apparent in persons without known diabetes. Persons with hemoglobin A1c concentrations less than 5% had the lowest rates of cardiovascular disease and mortality. An increase in hemoglobin A1c of 1 percentage point was associated with a relative risk for death from any cause of 1.24 (95% CI, 1.14 to 1.34; P < 0.001) in men and with a relative risk of 1.28 (CI, 1.06 to 1.32; P < 0.001) in women. These relative risks were independent of age, body mass index, waist-to-hip ratio, systolic blood pressure, serum cholesterol concentration, cigarette smoking, and history of cardiovascular disease. When persons with known diabetes, hemoglobin A(1c) concentrations of 7% or greater, or a history of cardiovascular disease were excluded, the result was similar (adjusted relative risk, 1.26 [CI, 1.04 to 1.52]; P = 0.02). Fifteen percent (68 of 521) of the deaths in the sample occurred in persons with diabetes (4% of the sample), but 72% (375 of 521) occurred in persons with HbA1c concentrations between 5% and 6.9%. LIMITATIONS: Whether HbA1c concentrations and cardiovascular disease are causally related cannot be concluded from an observational study; intervention studies are needed to determine whether decreasing HbA1c concentrations would reduce cardiovascular disease.
CONCLUSIONS: The risk for cardiovascular disease and total mortality associated with hemoglobin A1c concentrations increased continuously through the sample distribution. Most of the events in the sample occurred in persons with moderately elevated HbA1c concentrations. These findings support the need for randomized trials of interventions to reduce hemoglobin A1c concentrations in persons without diabetes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15381514     DOI: 10.7326/0003-4819-141-6-200409210-00006

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  279 in total

1.  Low hemoglobin A1c and risk of all-cause mortality among US adults without diabetes.

Authors:  April P Carson; Caroline S Fox; Darren K McGuire; Emily B Levitan; Martin Laclaustra; Devin M Mann; Paul Muntner
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-10-05

2.  Racial disparities in all-cause mortality among veterans with type 2 diabetes.

Authors:  Cheryl P Lynch; Mulugeta Gebregziabher; Carrae Echols; Gregory E Gilbert; Yumin Zhao; Leonard E Egede
Journal:  J Gen Intern Med       Date:  2010-06-08       Impact factor: 5.128

3.  Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds.

Authors:  S Zoungas; J Chalmers; T Ninomiya; Q Li; M E Cooper; S Colagiuri; G Fulcher; B E de Galan; S Harrap; P Hamet; S Heller; S MacMahon; M Marre; N Poulter; F Travert; A Patel; B Neal; M Woodward
Journal:  Diabetologia       Date:  2011-12-21       Impact factor: 10.122

Review 4.  Glycemic control and weight reduction without causing hypoglycemia: the case for continued safe aggressive care of patients with type 2 diabetes mellitus and avoidance of therapeutic inertia.

Authors:  Stanley S Schwartz; Benjamin A Kohl
Journal:  Mayo Clin Proc       Date:  2010-11-24       Impact factor: 7.616

5.  Dysglycaemia, dyslipidaemia and hypertension: risk factors primarily focused on the disease or risk estimates primarily focused on the patient?

Authors:  H C Gerstein
Journal:  Diabetologia       Date:  2010-11-20       Impact factor: 10.122

Review 6.  Canonical transient receptor potential channels in diabetes.

Authors:  Sarabeth Graham; Joseph P Yuan; Rong Ma
Journal:  Exp Biol Med (Maywood)       Date:  2012-01-26

7.  Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.

Authors:  Ruth McPherson; Jiri Frohlich; George Fodor; Jacques Genest
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

8.  Morphological assessment of pancreatic islet hormone content following aerobic exercise training in rats with poorly controlled Type 1 diabetes mellitus.

Authors:  Matthew W McDonald; Michael R Murray; Katharine E Hall; Earl G Noble; C W James Melling
Journal:  Islets       Date:  2014       Impact factor: 2.694

Review 9.  Cardiovascular outcomes in trials of oral diabetes medications: a systematic review.

Authors:  Elizabeth Selvin; Shari Bolen; Hsin-Chieh Yeh; Crystal Wiley; Lisa M Wilson; Spyridon S Marinopoulos; Leonard Feldman; Jason Vassy; Renee Wilson; Eric B Bass; Frederick L Brancati
Journal:  Arch Intern Med       Date:  2008-10-27

10.  [Early determinants of random blood glucose among adults of the 1982 birth cohort, Pelotas, Southern Brazil].

Authors:  Bernardo L Horta; Denise P Gigante; Cesar G Victora; Fernando C Barros; Isabel Oliveira; Vera Silveira
Journal:  Rev Saude Publica       Date:  2008-12       Impact factor: 2.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.